The challenge to effectively and safely restore proper control of blood glucose (sugar) levels (referred to as glycemic control) in people with diabetes is ongoing. The standard treatment for type 1 diabetes remains to be proper monitoring of blood glucose levels with daily insulin injections. However, patient compliance often limits its effectiveness. Pancreas transplantation is associated with limited donor tissue availability and with side effects due to the immune system suppression needed to reduce the risk of tissue rejection.
A long-awaited discovery leads researchers to find the pathogenic T cells that recognize and destroy pancreatic beta cells.
When it comes to autoimmune diseases, the patient’s main problem lies within. In such diseases, the immune system’s T cells go rogue and start attacking different organs, resulting in disease. Scientists are constantly trying to discover the identity of the autoimmune T cells as this may be the first step in a preventative therapy.
New research suggests that metformin treatment could effectively eliminate pancreatic cancer stem cells that rely on oxygen-based metabolism for energy production.
Pancreatic cancer is the fourth most common cause of cancer death, because of its tendency to cause symptoms only at a late and advanced stage. There were 49,000 new cases of the disease in 2015 in the United States; only 7.2% survive beyond 5 years. In most cases, by the time signs and symptoms appear, complete surgical removal is not possible and the cancer has already spread to other organs. Thus, development of strategies for earlier detection and new treatments are necessary to improve the prognosis of pancreatic cancer patients.
Mice studies show that the use of an antibody towards NK cells could reduce the development of diabetes in susceptible populations.
Redistributing immune cells through unpacking and repacking stem cells in the bone marrow shows promise in type 1 diabetes.